pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
VX21-147-301
Phase 3 · small molecule · APOL1-mediated Proteinuric Kidney Disease (AMKD)
VX21-147-301 for APOL1-mediated Proteinuric Kidney Disease (AMKD) is a Phase 3 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).
Internal code VX21-147-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- APOL1-mediated Proteinuric Kidney Disease (AMKD)
- Status
- active
- Trials
- 1